Last reviewed · How we verify
Amevive (ALEFACEPT)
Amevive (Alefacept) is a CD2-directed LFA-3/Fc Fusion Protein developed by Astellas, targeting T-cell surface antigen CD2. It is a small molecule drug class, FDA-approved in 2003 for the treatment of plaque psoriasis. Amevive works by binding to CD2 on T-cells, leading to their depletion and subsequent reduction in inflammation. The commercial status of Amevive is patented, and it is currently owned by Astellas. Key safety considerations include potential infections and allergic reactions.
At a glance
| Generic name | ALEFACEPT |
|---|---|
| Sponsor | Astellas Pharma |
| Drug class | CD2-directed LFA-3/Fc Fusion Protein |
| Target | T-cell surface antigen CD2 |
| Modality | Recombinant protein |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 2003 |
Approved indications
- Plaque psoriasis
Common side effects
Key clinical trials
- Safety and Tolerability of Repeat Courses of IM Alefacept (PHASE3)
- Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma (PHASE1)
- Alefacept in Patients With Severe Scalp Alopecia Areata (NA)
- Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis (NA)
- Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis (PHASE4)
- A Pilot Study of Alefacept for the Treatment of Pityriasis Rubra Pilaris (PHASE4)
- Alefacept in Patients With Relapsed/Refractory Aplastic Anemia (PHASE1)
- Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amevive CI brief — competitive landscape report
- Amevive updates RSS · CI watch RSS
- Astellas Pharma portfolio CI